Verily vs Hims & Hers

Side-by-side comparison of AI visibility scores, market position, and capabilities

Hims & Hers leads in AI visibility (86 vs 74)
Verily logo

Verily

LeaderDigital Health

Precision Health AI

Raised $300M (Mar 2026) led by Series X Capital. Became independent corporation; Alphabet now minority investor. Partners include Samsung Galaxy Watch 8 and Salesforce.

AI VisibilityBeta
Overall Score
B74
Category Rank
#79 of 596
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
74
Gemini
75

About

Verily is a precision health AI company that became independent from Alphabet (Google's parent) in March 2026 when it raised $300 million led by Series X Capital, transitioning Alphabet to a minority investor. The independence marks a major strategic inflection: Verily now competes as a standalone health AI platform rather than operating as a Google moonshot project, with the commercial accountability that comes with external capital and institutional investors.

Full profile
Hims & Hers logo

Hims & Hers

EmergingHealthcare

Telehealth Pharmacy

Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.

AI VisibilityBeta
Overall Score
A86
Category Rank
#8 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
92
Gemini
83

About

Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.

Full profile

AI Visibility Head-to-Head

74
Overall Score
86
#79
Category Rank
#8
87
AI Consensus
79
stable
Trend
stable
71
ChatGPT
88
74
Perplexity
92
75
Gemini
83
77
Claude
90
74
Grok
89

Key Details

Category
Precision Health AI
Telehealth Pharmacy
Tier
Leader
Emerging
Entity Type
company
brand

Capabilities & Ecosystem

Capabilities

Only Verily
Precision Health AI
Only Hims & Hers
Telehealth Pharmacy
Verily is classified as company (part of Google).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.